Pomalidomide has been authorised in the EU as Imnovid since 5 August 2013.
On 8 October 2009, orphan designation (EU/3/09/672) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for pomalidomide for the treatment of multiple myeloma.
The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.
|Disease / condition||
Treatment of multiple myeloma
|Date of first decision||
|EU designation number||
Review of designation
During its meeting of 11-13 June 2013, the Committee for Orphan Medicinal Products (COMP) reviewed the designation EU/3/09/672 for Imnovid, previously Pomalidomide Celgene, (pomalidomide) as an orphan medicinal product for the treatment of multiple myeloma. The COMP assessed whether, at the time of marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the condition, and the existence of other satisfactory methods of treatment. As other methods of treatment for patients with this condition are authorised in the European Union (EU), the COMP also looked at the significant benefit of the product over existing treatments. The COMP recommended that the orphan designation of the medicine be maintained*.
*The maintenance of the orphan designation at time of marketing authorisation would, except in specific situations, give an orphan medicinal product 10 years of market exclusivity in the EU. This means that in the 10 years after its authorisation similar products with a comparable therapeutic indication cannot be placed on the market.
For a list of the administrative updates please refer to the PDF document below.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.